PRINT ISSN: 0258-851X
ONLINE ISSN: 1791-7549
In Vivo is an international journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. IN VIVO was established in 1987 by J.G. Delinasios. In this site you may find information concerning the editorial board, editorial policy, submission of manuscripts, contents of previous volumes and a current list of accepted manuscripts.
All articles on SARS-Cov-2 and Covid-19 Disease can now be accessed here
The IN VIVO Special Issue on SARS-Cov-2 and Covid-19 Disease
is available OPEN ACCESS at Highwire
Original articles and reviews on SARS-Cov-2 and Covid-19 Disease are welcome to be submitted to
IN VIVO for peer-review and rapid publication upon acceptance
Diabetes: New Antidiabetic Agents; Stem Cell Therapy; Pancreas Transplantation – 2025
1. TOPICS: A. New Antidiabetic Agents
1. Development of novel antidiabetic drugs
2. Overcoming drug resistance
3. Combination therapies
B. Stem Cell Therapy in Diabetes
1. Stem cell-based regenerative therapies
2. Stem cell-derived pancreatic cells
3. Overcoming immune rejection in stem cell therapy
C. Pancreas Transplantation
1. Advances in pancreas transplant techniques
2. Pancreatic islet transplantation
3. Immunosuppression in pancreas transplantation
2. Deadline for article(s) submission: September 30, 2025.
3. The instructions to Authors of ΙN VIVO apply to this special issue, in the same way they apply to any ΙN VIVO issue.
4. Upon acceptance, Authors will be asked to pay an online publication fee of USD 1,000 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged.
5. All submitted articles will be peer-reviewed. Upon acceptance each article will be edited for language and style improvements (if needed and at no cost) by our philological department. Authors will receive a response within 3-4 weeks from submission.
6. The special issue is scheduled for publication in January 2026.
7. Manuscripts should be submitted for publication through our new online submission system: www.iiar-submissions.com
Contents of Current Issue
Archive of All Online Issues (January 2004 – Present)
 |
|
ANTICANCER RESEARCH USA, Inc.
111 Bay Avenue, Highlands, NJ 07732, USA.
e-mail: journals@iiar-anticancer.org
Information – Editorial & Production Office:
Managing Editor: G. J. Delinasios, International Institute of Anticancer Research,
1st km Kapandritiou- Kalamou Rd., P.O.Box 22, Kapandriti, Attiki 19014, Greece.
Tel & Fax : +30-22950-52945, +30-22950-53389
e-mail:journals@iiar-anticancer.org